Measuring leftover tumor cells in IDH-mutant glioma
Part of Cancer clinical trials.
This study looks at tumor tissue from people with a type of brain tumor called IDH-mutant glioma. The goal is to find better ways to measure how many tumor cells remain after treatment, which could help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a newly diagnosed glioma (a type of brain tumor) that is known or suspected to have an IDH mutation.
- You must be scheduled for a biopsy or surgery to remove the tumor at NYU Langone Health.
- You must not have an active hepatitis C infection or a prion disease (such as Creutzfeldt-Jakob disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of PET/MRI scan to look for a common genetic change (IDH mutation) in brain tumors (gliomas). The goal is to improve how doctors diagnose and treat these tumors.
This trial studies whether changes in RNA (the instructions inside cells) can help doctors better diagnose and treat gliomas, a type of brain tumor. If you are scheduled for surgery to remove a suspected glioma and have not had prior treatment, you may be able to join.
This study looks at the chemicals and genes in brain tumors called gliomas to find better ways to diagnose and treat them. People with a brain mass that needs surgery may be able to join.
This study analyzes tissue and health-related biological data from people with glioblastoma to learn what’s happening in the tumor. The results may help improve future ways to understand and treat glioblastoma using advanced computer analysis.
This study is collecting information about people in Brazil who have been diagnosed with a type of brain tumor that has an IDH mutation. It aims to better understand the disease and support future research, without giving new treatments.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.